Krystal Biotech Form 4: 5k options awarded to board member

Rhea-AI Filing Summary

On 30 June 2025, Krystal Biotech (KRYS) filed a Form 4 reporting that independent director Julian S. Gangolli received 5,000 stock options with an exercise price of $137.46 and a 10-year term expiring 30 June 2035. The award vests in 12 equal monthly tranches through June 2026, aligning the director’s incentives with shareholder value over the next year. No common shares were bought or sold, and the grant represents potential dilution of well under 0.1 % of outstanding shares, making it immaterial from a capitalization standpoint.

Insights

Securities Analyst

TL;DR: Routine 5k-option grant to KRYS director; negligible dilution and no trading signal—overall neutral.

The filing shows a standard equity incentive grant to director Julian Gangolli. The strike price equals the market price, so no intrinsic value is transferred today. Vesting over 12 months encourages short-term board continuity. With approximately 26 million shares outstanding, 5,000 options translate to less than 0.02 % potential dilution—too small to move valuation models. There are no sales, purchases, or multi-party arrangements that might hint at sentiment or forthcoming corporate events. As such, the disclosure is routine, governance-aligned, and financially immaterial.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gangolli Julian S

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PA 15203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$137.46	06/30/2025		A		5,000		(1)	06/30/2035	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The options were awarded on June 30, 2025 and vest in equal monthly tranches over a one-year period.

Remarks:

	/s/ Krish Krishnan, as attorney-in-fact for Julian S. Gangolli	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Krystal Biotech (KRYS) disclose in the June 30 2025 Form 4?

The company granted 5,000 stock options to director Julian S. Gangolli at a $137.46 strike price.

When do the newly granted KRYS options vest?

They vest in equal monthly installments over one year, fully vesting by June 2026.

What is the expiration date of the options granted to Julian S. Gangolli?

The options expire on 30 June 2035.

Does the Form 4 report any open-market purchases or sales of KRYS stock?

No. The filing only reports an option grant; no common shares were bought or sold.

How much potential dilution could the 5,000 options cause?

At under 0.1 % of outstanding shares, the dilution is immaterial.